L1
2.0
amendment
samdt3614-119
samdt3614-119
Amendment to: FY2026 National Defense Authorization Act (NDAA, Senate vehicle)
Why China-relevant: People's Republic of China
Sponsor: Risch, James E.
Timeline
- Filed
- Passed chamber (vote) [senate]vehicle
Vehicle: FY2026 National Defense Authorization Act (NDAA, Senate vehicle)
- Introduced
- Passed committee
- Passed Senate
- Passed House next step
- Sent to President
- Became law
done next step still ahead
Stage: Passed Senate
18% to become law · 94% to clear committee
- + Is/rides a must-pass vehicle (NDAA or appropriations)
- + Sponsored by a member of the majority party
- − No cosponsors
Legislative likelihood — a tracking indicator, not investment advice.
Signals — secondary, directional
PRC retaliation risk
low
Hawkishness 1–5
4
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
domain 'fentanyl' -> pharma_china via stock_mapping.yaml (coarse fallback)
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |